Recruitment

Topics Included: Ensuring Quality, Recruitment

In order to ensure your trial has adequate recruitment, you have to plan for it. It sounds simple, but a primary reason why clinical trials stop early is because of a failure to enroll enough participants.   

Meet your recruitment goals and help ensure the successful completion of your clinical trial by using CTTI’s recommendations for strategic recruitment planning. With this framework, you can explore new approaches to recruitment and learn how to help meet enrollment numbers by conducting evidence-based trial feasibility analyses and selecting the most appropriate sites.  

Resources

Recruitment

Recruitment

In order to ensure your trial has adequate recruitment, you have to plan for it. It sounds simple, but a primary reason why clinical trials stop early is because of...

Safety

Pregnancy Testing

Pregnant women have traditionally been excluded from clinical research – however, until now, there were no guidelines for planning for pregnancy testing in clinical trials.

Clinical Trials Landscape

State of Clinical Trials

One of the initial steps to improving clinical trials is to document the current state of clinical trials in order to track changes over time.

Site Planning | CTTI News

New Paper Offers Recommendations for Efficient Identification and Training of Investigators

CTTI has released a new preprint paper describing its recommended approach for identifying and preparing investigators and their delegates to perform clinical research. The paper suggests that by moving beyond Good Clinical...

Ensuring Quality | CTTI News

CTTI Webinar Highlights the Importance & Benefits of Quality by Design

A recent CTTI webinar brought together stakeholders from across the clinical trials enterprise for an overview of Quality by Design (QbD), existing CTTI resources, and how QbD is being implemented in the...

Regulatory Submissions + Approvals | CTTI News

CTTI to Launch Recommendations for Engaging Patient and Site Perspectives in Mobile Clinical Trials

CTTI will host a public webinar on Thurs., Feb. 21, to announce new recommendations and resources for incorporating patient and site perspectives when planning and conducting mobile clinical trials. “Acceptance and...

Safety | CTTI News

CTTI Article Outlines Recommendations for Pregnancy Testing in Clinical Trials

Most clinical trials exclude pregnant women in order to minimize risk to the embryo or fetus. However, there are currently no specific guidelines for how pregnancy testing should be conducted...

Ensuring Quality | Publications

Evidence-based pregnancy testing in clinical trials: Recommendations from a multi-stakeholder development process

Evidence-based pregnancy testing in clinical trials: Recommendations from a multi-stakeholder development process

CTTI News

CTTI Shares Latest Findings on Mobile Technology, Patient Engagement, and More at DIA 2018

At this year’s DIA 2018 Global Annual Meeting, CTTI will share insights across a broad range of topics that are core to its mission of enhancing the quality and efficiency of...

CTTI News

CTTI Releases 2017 Annual Report: One Decade of Impact. One Vision Ahead.

CTTI’s 2017 Annual Report, released today, celebrates a decade of CTTI impact and highlights our activities and accomplishments over the past year. The report includes reflections from past and present CTTI...

Formats

Stage of Trial

Pregnancy Testing

Topics Included: Ensuring Quality, Safety

Pregnant women have traditionally been excluded from clinical research – however, until now, there were no guidelines for planning for pregnancy testing in clinical trials.   

Sponsors, investigators, and institutional review boards can now use CTTI’s recommendations to develop and review pregnancy testing plans, assess the benefits and burdens of various options, and calculate how many participants may potentially enroll while pregnant or become pregnant during the study by using CTTI’s Pregnancy Testing Outcomes Predictor for Clinical Trials. 

The recommendations and interactive web application provide a standard way to plan for and make decisions about pregnancy testing in clinical trials, while also improving communication and transparency with trial participants. 

Resources

Recruitment

Recruitment

In order to ensure your trial has adequate recruitment, you have to plan for it. It sounds simple, but a primary reason why clinical trials stop early is because of...

Safety

Pregnancy Testing

Pregnant women have traditionally been excluded from clinical research – however, until now, there were no guidelines for planning for pregnancy testing in clinical trials.

Clinical Trials Landscape

State of Clinical Trials

One of the initial steps to improving clinical trials is to document the current state of clinical trials in order to track changes over time.

Site Planning | CTTI News

New Paper Offers Recommendations for Efficient Identification and Training of Investigators

CTTI has released a new preprint paper describing its recommended approach for identifying and preparing investigators and their delegates to perform clinical research. The paper suggests that by moving beyond Good Clinical...

Ensuring Quality | CTTI News

CTTI Webinar Highlights the Importance & Benefits of Quality by Design

A recent CTTI webinar brought together stakeholders from across the clinical trials enterprise for an overview of Quality by Design (QbD), existing CTTI resources, and how QbD is being implemented in the...

Regulatory Submissions + Approvals | CTTI News

CTTI to Launch Recommendations for Engaging Patient and Site Perspectives in Mobile Clinical Trials

CTTI will host a public webinar on Thurs., Feb. 21, to announce new recommendations and resources for incorporating patient and site perspectives when planning and conducting mobile clinical trials. “Acceptance and...

Safety | CTTI News

CTTI Article Outlines Recommendations for Pregnancy Testing in Clinical Trials

Most clinical trials exclude pregnant women in order to minimize risk to the embryo or fetus. However, there are currently no specific guidelines for how pregnancy testing should be conducted...

Ensuring Quality | Publications

Evidence-based pregnancy testing in clinical trials: Recommendations from a multi-stakeholder development process

Evidence-based pregnancy testing in clinical trials: Recommendations from a multi-stakeholder development process

CTTI News

CTTI Shares Latest Findings on Mobile Technology, Patient Engagement, and More at DIA 2018

At this year’s DIA 2018 Global Annual Meeting, CTTI will share insights across a broad range of topics that are core to its mission of enhancing the quality and efficiency of...

CTTI News

CTTI Releases 2017 Annual Report: One Decade of Impact. One Vision Ahead.

CTTI’s 2017 Annual Report, released today, celebrates a decade of CTTI impact and highlights our activities and accomplishments over the past year. The report includes reflections from past and present CTTI...

Formats

Stage of Trial

State of Clinical Trials

Topics Included: Clinical Trials Landscape

One of the initial steps to improving clinical trials is to document the current state of clinical trials in order to track changes over time. Researchers can use CTTI’s Aggregate Analysis of ClinicalTrial.gov (AACT) database to easily access and analyze data from the ClinicalTrials.gov registry to evaluate studies and characterize the current state of clinical trials.

As an example of the power of the database, CTTI created the AACT COVID-19 Trials Spreadsheet, a searchable spreadsheet of COVID-19-related studies posted on ClinicalTrials.gov.

CTTI has issued a number of key publications – including, "Characteristics of Clinical Trials Registered in ClinicalTrials.gov," "The Database for AACT and Subsequent Regrouping by Clinical Specialty," and "Compliance with Results Reporting at ClinicalTrials.gov" (plus dataset file here) – to document the state of clinical trials over time. Most recently, it delivered an update via The State of U.S. COVID-19 Treatment Clinical Trials webinar.

 

Resources

Recruitment

Recruitment

In order to ensure your trial has adequate recruitment, you have to plan for it. It sounds simple, but a primary reason why clinical trials stop early is because of...

Safety

Pregnancy Testing

Pregnant women have traditionally been excluded from clinical research – however, until now, there were no guidelines for planning for pregnancy testing in clinical trials.

Clinical Trials Landscape

State of Clinical Trials

One of the initial steps to improving clinical trials is to document the current state of clinical trials in order to track changes over time.

Site Planning | CTTI News

New Paper Offers Recommendations for Efficient Identification and Training of Investigators

CTTI has released a new preprint paper describing its recommended approach for identifying and preparing investigators and their delegates to perform clinical research. The paper suggests that by moving beyond Good Clinical...

Ensuring Quality | CTTI News

CTTI Webinar Highlights the Importance & Benefits of Quality by Design

A recent CTTI webinar brought together stakeholders from across the clinical trials enterprise for an overview of Quality by Design (QbD), existing CTTI resources, and how QbD is being implemented in the...

Regulatory Submissions + Approvals | CTTI News

CTTI to Launch Recommendations for Engaging Patient and Site Perspectives in Mobile Clinical Trials

CTTI will host a public webinar on Thurs., Feb. 21, to announce new recommendations and resources for incorporating patient and site perspectives when planning and conducting mobile clinical trials. “Acceptance and...

Safety | CTTI News

CTTI Article Outlines Recommendations for Pregnancy Testing in Clinical Trials

Most clinical trials exclude pregnant women in order to minimize risk to the embryo or fetus. However, there are currently no specific guidelines for how pregnancy testing should be conducted...

Ensuring Quality | Publications

Evidence-based pregnancy testing in clinical trials: Recommendations from a multi-stakeholder development process

Evidence-based pregnancy testing in clinical trials: Recommendations from a multi-stakeholder development process

CTTI News

CTTI Shares Latest Findings on Mobile Technology, Patient Engagement, and More at DIA 2018

At this year’s DIA 2018 Global Annual Meeting, CTTI will share insights across a broad range of topics that are core to its mission of enhancing the quality and efficiency of...

CTTI News

CTTI Releases 2017 Annual Report: One Decade of Impact. One Vision Ahead.

CTTI’s 2017 Annual Report, released today, celebrates a decade of CTTI impact and highlights our activities and accomplishments over the past year. The report includes reflections from past and present CTTI...

Formats

Stage of Trial

New Paper Offers Recommendations for Efficient Identification and Training of Investigators

CTTI has released a new preprint paper describing its recommended approach for identifying and preparing investigators and their delegates to perform clinical research. The paper suggests that by moving beyond Good Clinical Practice (GCP) training as a one-size-fits-all solution, sponsors, CROs, investigators, and other research professionals may be able to more efficiently find and train investigators for quality research.

Specifically, CTTI recommends complementing previous GCP training with a fit-for-purpose, risk-based training approach to close identified gaps in knowledge or skills. This multifaceted approach to training can enrich understanding of how GCP principles apply to the conduct of a particular clinical trial and help investigators grasp how to better apply quality principles in a specific setting. Combining the real-world application of GCP principles with role- and protocol-specific instruction has the potential to add greater value to the investigator qualification process, leading to the higher quality conduct of trials.

CTTI used findings from qualitative research with investigators and clinical trial sponsors, along with input from an expert meeting with multiple stakeholders, to develop the recommendations. The research identified gaps and redundancies in the current training of investigators and their delegates, as well as a common theme: the didactic, one-size-fits-all approach most commonly used for training investigators and documenting their qualification often introduces redundancies and minimizes the value of previous training.

In the paper, CTTI offers detailed recommendations for how sponsors, CROs, and site teams can respond to these insights and positively shift the investigator training culture, as well as further discussion of how a targeted learning approach can better prepare investigators and their delegates to conduct quality clinical trials.

CTTI Webinar Highlights the Importance & Benefits of Quality by Design

A recent CTTI webinar brought together stakeholders from across the clinical trials enterprise for an overview of Quality by Design (QbD), existing CTTI resources, and how QbD is being implemented in the real world.

QbD is defined as the absence of “errors that matter”—or, those errors that could jeopardize the ability to 1) protect patients during the trial, and 2) obtain reliable results and meaningful information from the trial. CTTI started working on QbD in 2011, with a focus on addressing ineffective clinical trial monitoring. It was determined that monitoring should be viewed as only one component of an overall quality framework. From there, CTTI went on to develop a broad set of evidence-based recommendations and resources to help drive adoption of QbD.

During the webinar, CTTI walked stakeholders through its QbD Toolkit, which is split into three sections that allow users to:

  • Learn about QbD;
  • Introduce QbD to their organizations via workshops and printable resources; and
  • Adopt QbD within their organizations.

CTTI also reviewed other available resources, such as the QbD Principles document, a key tool for QbD implementation.

Jean Mulinde, a senior policy advisor for the FDA, then spoke about why quality is important to clinical trials.

“QbD should be implemented at the clinical trial level and may be one component of an organization’s overarching quality management system,” Mulinde said. “Implementing QbD serves to focus the protocol and all of the operational plans necessary to implement the protocol on critical processes and data from the outset of a trial.”

Representatives from both academic and private organizations also shared their successes in QbD implementation. Hamid Moradi, a faculty member and researcher at University of California-Irvine, said that his organization hosted a CTTI-led QbD workshop to increase buy-in, which received a positive response from attendees. Moradi also discussed the QbD working group established at UC Irvine.

“This team will be a resource to investigators to help them better design and conduct their trials using QbD principles,” he said.

Currently, CTTI is working on additional QbD resources to support implementation, which it aims to announce within the next year.

CTTI to Launch Recommendations for Engaging Patient and Site Perspectives in Mobile Clinical Trials

CTTI will host a public webinar on Thurs., Feb. 21, to announce new recommendations and resources for incorporating patient and site perspectives when planning and conducting mobile clinical trials.

“Acceptance and adoption by key stakeholders is critical to the widespread use of mobile technologies in clinical trials,” said CTTI Executive Director Pamela Tenaerts. “However, very little was known about patient and sites’ perspectives until our work shed light on what they see as significant benefits and barriers. Our new recommendations account for these perspectives and provide a valuable resource for optimally deploying mobile clinical trials.

“Further, they build on previous CTTI work—including our Quality by Design and Patient Groups and Clinical Trials recommendations—that emphasizes the involvement of many stakeholders, including patients and sites, in trial design. Engaging these groups early and often is the key to running better trials.”

CTTI conducted surveys and in-depth interviews to better understand the perceptions of patients and clinical investigators, and convened experts and leaders across the clinical trials enterprise to develop actionable recommendations and resources.

The resulting recommendations are designed to assist research sponsors in:

  • Engaging patient and site perspectives in planning clinical trials using mobile technologies, including protocol design, technology selection, and pilot testing
  • Maximizing value and minimizing burden for study participants, including setting patient expectations, protecting privacy, returning individual data, enhancing patient-site interactions, and providing technical support
  • Addressing challenges for investigative sites, from contracting and budgeting to evaluating site readiness and implementing effective and streamlined training

This is the final of four sets of recommendations CTTI has released as part of its Mobile Clinical Trials (MCT) Program. In 2017, CTTI announced recommendations for developing novel endpoints generated by mobile technologies and, in 2018, it unveiled new solutions for using mobile technologies for data capture in clinical trials, and recommendations for planning and conducting decentralized clinical trials.

The free webinar will begin at noon ET and will be led by patient advocate Cindy Geoghegan and Virginia Nido of Genentech, a member of the Roche Group.

CTTI Article Outlines Recommendations for Pregnancy Testing in Clinical Trials

Most clinical trials exclude pregnant women in order to minimize risk to the embryo or fetus. However, there are currently no specific guidelines for how pregnancy testing should be conducted for female trial participants of reproductive potential, nor how risks should be clearly communicated with them.

In a recent article in PLOS ONE, CTTI shares recommendations developed by experts in academia, industry, and regulatory agencies on pregnancy testing in clinical research. They include the following:

  • The study protocol should clearly state the rationale for pregnancy testing and the plan for handling positive and indeterminate tests.
  • Investigators should assess the balance of the advantages and burdens of the pregnancy testing plan, as well as and evaluate participant burdens regarding the likelihood of false-negative and false-positive results.
  • Participant-administered home pregnancy testing should be avoided in clinical trials.
  • The consent process should describe what is known about the study intervention’s potential risk to an embryo or fetus and the limitations and consequences of pregnancy testing.

CTTI also developed an online tool to estimate the potential outcomes of different pregnancy testing strategies in the proposed trial population. Together, these resources aim to help research sponsors, investigators, and institutional review boards create and review pregnancy testing plans, in an effort to conduct safer, more efficient clinical trials.

CTTI Shares Latest Findings on Mobile Technology, Patient Engagement, and More at DIA 2018

At this year’s DIA 2018 Global Annual Meeting, CTTI will share insights across a broad range of topics that are core to its mission of enhancing the quality and efficiency of clinical trials. During the event, which will take place in Boston from June 24-28, CTTI will take part in 10 different presentations and sessions in areas ranging from patient-focused medical development to the use of mobile technology for data capture to quality approaches to clinical trial design.

 

Please join us at the CTTI exhibitor booth (#1624) and attend our presentations:

 

Presentation: The Metamorphasis of Clinical Trials: Evolving Roles of Stakeholders in Digital Trials
Date & Time: Mon., June 25, 11:00 a.m. – 12:00 p.m.
Presenters:  Angela Botto-van Bemden (Arthritis Foundation)
Related CTTI Project: MCT Stakeholder Perceptions

 

Presentation: Patient-Focused Medicines Development: Where It Has Led Us Today, What Challenges Remain and What Do We Still Need to Do to Achieve Success?
Date & Time: Mon., June 25, 11:00 a.m. – 12:15 p.m.
Presenter: Pamela Tenaerts (CTTI)

Related CTTI Projects: Patient Groups & Clinical Trials

 

Presentation: The Who, What, How, When, and Why of Using Mobile Technology in Clinical Trials
Date & Time: Mon., June 25, 11:00 a.m. – 12:15 p.m.

Chair: Robert DiCicco (TransCelerate Biopharma)
Presenters:  Philip Coran (Medidata Solutions), Cindy Geoghegan (Individual Patient/Caregiver), and Jan Hewett (FDA/CDER)
Related CTTI Project: MCT Mobile Technologies

 

Engage & Exchange Session: New Approaches, Novel Endpoints, and Next-Generation Trials
Date & Time: Mon., June 25, 1:45 – 2:45 p.m.

Chair: Jennifer Goldsack (CTTI)
Facilitators: Jessie Bakker (Philips Respironics), Daniel Karlin (Pfizer), and Komathi Stem (monARC Bionetworks)

Related CTTI Project: MCT Novel Endpoints

 

Presentation: A Quality-by-Design Approach to Trial Design and Conduct: Case Studies from the Clinical Trials Transformation Initiative
Date & Time: Mon., June 25, 3:00 – 4:15 p.m.

Chair: Annemarie Forrest (CTTI)
Presenters: Sabrina Comic-Savic (The Medicines Company) and Julie Dietrich (Amgen)
Related CTTI Project: Quality by Design

 

Content Hub: Developing Standards to Support the Use of Wearables and Sensors for Objective Data Collection During Clinical Trials
Date & Time: Tues., June 26, 1:30 – 2:00 p.m.
Presenter: Jennifer Goldsack (CTTI)
Related CTTI Project: MCT Mobile Technologies

 

Presentation: Debunking Decentralized Trials: Sharing Breakthroughs and Deal Breakers

Date & Time: Tues., June 26, 4:15 – 5:30 p.m.

Chair: Jane Myles (Genentech – a member of the Roche group)
Presenters: Gerrit Hamre (CTTI), Leonard Sacks (FDA/CDER), and Komathi Stem (monARC Bionetworks)
Related CTTI Project:  MCT Mobile Technologies, MCT Novel Endpoints

 

Presentation: Building up Efficiencies, Breaking Down Barriers: Using Mobile Technology for Data Capture in Clinical Trials

Date & Time: Tues., June 26, 4:15 – 5:30 p.m.
Presenters: Sunil Agarwal (HCL America) and James Streeter (Oracle)
Related CTTI Project: MCT Data Collection

 

Presentation: Redefining the Site Investigator’s Experience

Date & Time: Tues., June 26, 4:15 – 5:30 p.m.
Presenters: Kaitlin Malone (Amgen)

Related CTTI Project: Investigator Community

 

Presentation: Data and Quality Approaches to Informing Global Investigative Site Selection

Date & Time: Wed., June 27, 8:00 – 9:15 a.m.

Chair: Stella Stergiopoulos (Tufts Center for the Study of Drug Development)
Presenter: James Kremidas (ACRP)
Related CTTI Project: Investigator Qualification

 

Poster: Effective Engagement Between Sponsors & Patient Groups: A Structured Process and Use Cases from CTTI

Date & Time: Wed., June 27, 9:30 – 10:30 a.m., 12:00 – 2:00 p.m., 3:00 – 4:00 p.m.

Presenter: Zach Hallinan (CTTI)

Related CTTI Project: Patient Groups & Clinical Trials

CTTI Releases 2017 Annual Report: One Decade of Impact. One Vision Ahead.

CTTI’s 2017 Annual Report, released today, celebrates a decade of CTTI impact and highlights our activities and accomplishments over the past year. The report includes reflections from past and present CTTI leaders, case studies on the use of CTTI recommendations and resources, and a glimpse into what lies ahead for CTTI and the clinical trials enterprise.

Since its founding in 2007, CTTI has completed more than 25 projects with the aim of increasing the quality and efficiency of clinical trials. The resulting recommendations were downloaded more than 26,000 times over the past year.

CTTI issued five new sets of recommendations in 2017, many of which draw on recent advances in technology and data sciences to bring about improvements for clinical trials. Read the report to learn more about our latest recommendations and resources, which offer:

As described in the report, these recommendations and resources are being implemented by organizations across the clinical trial spectrum, including IQVIA, monARC Bionetworks, and the Pulmonary Fibrosis Foundation.

As we reflect on the past year—and the past decade—we are grateful for the engagement and commitment of our members, who ensure that we continue to address the latest trends, top barriers, and leading opportunities in clinical research.